Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06897202 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Efficacy and Safety of Once-Weekly MET097 in Adults With Obesity or Overweight and T2DM
A Phase 2 study of Type 2 Diabetes Mellitus (T2DM) and Obesity in Diabetes, sponsored by Metsera, a wholly owned subsidiary of Pfizer.
- Active
- Registry status
- Phase 2
- Development phase
- 133
- Enrollment target
- 20
- Study locations
NCT06897202: Active Phase 2 study of Type 2 Diabetes Mellitus (T2DM) and Obesity in Diabetes, sponsored by Metsera, a wholly owned subsidiary of Pfizer.
NCT06897202 is a Phase 2 study of Type 2 Diabetes Mellitus (T2DM) and Obesity in Diabetes that is active but no longer recruiting, run by Metsera, a wholly owned subsidiary of Pfizer. The registered enrollment target is 133 participants, below the 517-participant average among 24 other Type 2 Diabetes Mellitus (T2DM) trials with a reported enrollment target (74% lower). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06897202, a Phase 2 study of Type 2 Diabetes Mellitus (T2DM) and Obesity in Diabetes, is active but no longer recruiting, sponsored by Metsera, a wholly owned subsidiary of Pfizer.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 133 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is designed to test how well once-weekly MET097 (an ultra-long-acting GLP-1 receptor agonist) works to treat adults with obesity or overweight and type 2 diabetes mellitus (T2DM) compared to placebo. MET097 or placebo will be administered to individuals via subcutaneous injection once weekly for 28 weeks. If an individual is randomly assigned to MET097 they will receive one of four different dose regimens.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG MET097 Injection
Study Locations (20)
California
- Research Site US-97202-001012 - Chula Vista
- Research Site US-97202-001019 - Los Alamitos
- Research Site US-97202-001021 - Los Angeles
- Research Site US-97202-001007 - Riverside
Florida
- Research Site US-97202-001024 - Bradenton
- Research Site 097202-001001 - Hollywood
- Research Site 097202-001003 - Tampa
Georgia
- Research Site 097202-001002 - Decatur
- Research Site US-97202-001009 - Riverdale
- Research Site 097202-001005 - Savannah
Illinois
- Research Site US-97202-001017 - Morton
- Research Site US-97202-001022 - Naperville
Maryland
- Research Site US-97202-001015 - Columbia
- Research Site US-97202-001006 - Gaithersburg
Texas
- Research Site US-97202-001023 - Plano
- Research Site US-97202-001013 - Sherman
Kansas
- Research Site US-97202-001008 - Kansas City
New Jersey
- Research Site US-97202-001004 - Marlton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 133 participants |
| Start Date | 2025-03-14 |
| Est. Completion | 2026-03 |
| Phase | Phase 2 |
What the registry record for NCT06897202 still lists
NCT06897202 is an interventional study that assigns participants to a tested intervention. The registered 133 participants enrollment target is mid-sized for trials with a published cap, below the 517-participant average among 24 other Type 2 Diabetes Mellitus (T2DM) trials with a reported enrollment target (74% lower).
The record links to 2 conditions, with Type 2 Diabetes Mellitus (T2DM) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06897202 names 20 study sites across 10 states, led by California, Florida, Georgia.
Frequently Asked Questions
What is clinical trial NCT06897202 about?
NCT06897202 is a clinical study titled "A Study to Evaluate the Efficacy and Safety of Once-Weekly MET097 in Adults With Obesity or Overweight and T2DM". This study is designed to test how well once-weekly MET097 (an ultra-long-acting GLP-1 receptor agonist) works to treat adults with obesity or overweight and type 2 diabetes mellitus (T2DM) compared to placebo. MET097 or placebo will be administered to individuals via subcutaneous injection once wee...
What is the current status of trial NCT06897202?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 133 participants. The study started on 2025-03-14. Estimated completion is 2026-03.
What conditions does trial NCT06897202 study?
This clinical trial studies the following conditions: Type 2 Diabetes Mellitus (T2DM), Obesity in Diabetes.
What interventions are being tested in trial NCT06897202?
The interventions under investigation include: Placebo (DRUG), MET097 Injection (DRUG).
Who is sponsoring clinical trial NCT06897202?
This trial is sponsored by Metsera, a wholly owned subsidiary of Pfizer, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06897202 being conducted?
This trial has 20 study locations across California, Florida, Georgia, Illinois, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 2 Diabetes Mellitus (T2DM)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06897202's enrollment target sits among peer trials
133 14th of 24 higher than 11 of 24 other Type 2 Diabetes Mellitus (T2DM) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Type 2 Diabetes Mellitus (T2DM) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluate Use of Tropocells(R) Autologous Platelet-rich Fibrin (PRF) for Wagner Grade 1 and Grade 2, Mild to Mod Neuroischemic Plantar Diabetic Foot Ulcer Wound Care.
RECRUITING · Phase 2
-
Low-Dose Pioglitazone in Patients With NASH (AIM 2)
RECRUITING · Phase 2
-
A Study to Evaluate ALN-4324 on Insulin Sensitivity in Adults With Type 2 Diabetes Mellitus
RECRUITING · Phase 2
-
A Study of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus (T2DM)
ACTIVE NOT RECRUITING · Phase 2
-
A Study of CT-388 in Participants Who Are Overweight or Obese With Type 2 Diabetes Mellitus
ACTIVE NOT RECRUITING · Phase 2
-
Preventing Medication Mismanagement in People Living with Dementia Through Automated Medication Dispensing with Facial Recognition and Video Observation
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04276870 · 133 participants · Phase 2
Orphan Indications for CD19 Redirected Autologous T Cells
- NCT04671771 · 133 participants · NA
A Study to Evaluate the Safety and Effectiveness of the InnAVasc Arteriovenous Graft for Hemodialysis Access in Patients With End-Stage Renal Disease
- NCT05610085 · 133 participants · Phase 2
A Dose Escalation Study of Levetiracetam in the Treatment of Neonatal Seizures
- NCT06206486 · 133 participants
The Gut Microbiome and Serum Metabolites As a Biological Mechanism Underlying Pain in Kidney Transplantation
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI